See more : Bookoff Group Holdings Limited (9278.T) Income Statement Analysis – Financial Results
Complete financial analysis of Esperion Therapeutics, Inc. (ESPR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Esperion Therapeutics, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Xinda Investment Holdings Limited (1281.HK) Income Statement Analysis – Financial Results
- YG Plus, Inc. (037270.KS) Income Statement Analysis – Financial Results
- Harmonic Drive Systems Inc. (HSYDF) Income Statement Analysis – Financial Results
- Toyo Wharf & Warehouse Co., Ltd. (9351.T) Income Statement Analysis – Financial Results
- ASM (7706.TWO) Income Statement Analysis – Financial Results
Esperion Therapeutics, Inc. (ESPR)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.esperion.com
About Esperion Therapeutics, Inc.
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2002 | 2001 | 2000 | 1999 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 116.33M | 75.48M | 78.45M | 227.55M | 148.36M | 184.47M | 0.00 | 0.00 | 0.00 | 0.00 | 4.98B | 0.00 | 0.00 | 0.00 | 0.00 | 2.00K | 0.00 |
| Cost of Revenue | 43.27M | 26.97M | 14.22M | 2.39M | 175.61M | 265.00K | 258.00K | 252.00K | 236.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 786.00K | 683.22K |
| Gross Profit | 73.07M | 48.51M | 64.23M | 225.16M | -27.25M | 184.21M | -258.00K | -252.00K | -236.00K | 0.00 | 4.98B | 0.00 | 0.00 | 0.00 | 0.00 | -784.00K | -683.22K |
| Gross Profit Ratio | 62.81% | 64.27% | 81.88% | 98.95% | -18.36% | 99.86% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | -39,200.00% | 0.00% |
| Research & Development | 86.11M | 118.93M | 105.98M | 146.94M | 175.61M | 171.49M | 147.60M | 57.87M | 29.80M | 25.30M | 16.01M | 8.00M | 7.81M | 21.99M | 21.45M | 21.79M | 8.48M |
| General & Administrative | 126.92M | 97.78M | 171.29M | 180.32M | 65.85M | 33.10M | 21.38M | 18.28M | 20.24M | 10.92M | 6.74M | 2.21M | 2.36M | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 15.60M | 11.30M | 13.70M | 19.30M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 142.52M | 109.08M | 184.99M | 199.62M | 65.85M | 33.10M | 21.38M | 18.28M | 20.24M | 10.92M | 6.74M | 2.21M | 2.36M | 5.96M | 5.02M | 2.95M | 2.52M |
| Other Expenses | 0.00 | 2.65M | 3.98M | 515.00K | 4.06M | 2.78M | 2.19M | 1.55M | 776.00K | 119.00K | 194.01K | -83.65K | -75.81K | 0.00 | 0.00 | 5.00M | 3.20M |
| Operating Expenses | 228.63M | 228.01M | 290.96M | 346.55M | 241.47M | 204.59M | 168.98M | 76.15M | 50.04M | 36.22M | 22.76M | 10.20M | 10.16M | 29.24M | 29.33M | 26.79M | 11.69M |
| Cost & Expenses | 271.90M | 254.98M | 305.18M | 348.94M | 241.47M | 204.59M | 168.98M | 76.15M | 50.04M | 36.22M | 22.76M | 10.20M | 10.16M | 29.24M | 29.33M | 27.57M | 12.37M |
| Interest Income | 0.00 | 2.60M | 112.00K | 600.00K | 4.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 58.98M | 56.81M | 46.35M | 22.67M | 8.12M | 100.00K | 198.00K | 376.00K | 520.00K | 270.00K | 936.58K | 1.49M | 577.16K | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 164.00K | 500.00K | 612.00K | 547.00K | 319.00K | 265.00K | 258.00K | 252.00K | 236.00K | 160.00K | 70.55K | 139.43K | 178.47K | -1.29M | -2.01M | -2.05M | -683.22K |
| EBITDA | -150.11M | -176.35M | -222.14M | -120.33M | -88.73M | -204.32M | -166.53M | -74.35M | -49.03M | -36.06M | -22.69M | -10.12M | -10.06M | -27.22M | -26.80M | -25.52M | -11.69M |
| EBITDA Ratio | -129.03% | -234.31% | -283.96% | -53.12% | -60.02% | -110.90% | 0.00% | 0.00% | 0.00% | 0.00% | -0.45% | 0.00% | 0.00% | 0.00% | 0.00% | -1,086,150.00% | 0.00% |
| Operating Income | -155.56M | -179.50M | -226.73M | -121.40M | -93.10M | -204.59M | -168.98M | -76.15M | -50.04M | -36.22M | -22.76M | -10.20M | -10.16M | -27.95M | -27.32M | -27.57M | -12.37M |
| Operating Income Ratio | -133.72% | -237.83% | -289.02% | -53.35% | -62.75% | -110.90% | 0.00% | 0.00% | 0.00% | 0.00% | -0.46% | 0.00% | 0.00% | 0.00% | 0.00% | -1,378,600.00% | 0.00% |
| Total Other Income/Expenses | -53.69M | -54.16M | -42.38M | -22.16M | -4.06M | 2.78M | 1.99M | 1.17M | 256.00K | -151.00K | -3.33M | -1.54M | -652.97K | -780.00K | 2.39M | -3.80M | 0.00 |
| Income Before Tax | -209.25M | -233.66M | -269.11M | -143.55M | -97.17M | -201.81M | -166.99M | -74.98M | -49.78M | -36.38M | -26.09M | -11.74M | -10.82M | -28.73M | -24.93M | -31.37M | 0.00 |
| Income Before Tax Ratio | -179.87% | -309.58% | -343.04% | -63.09% | -65.49% | -109.40% | 0.00% | 0.00% | 0.00% | 0.00% | -0.52% | 0.00% | 0.00% | 0.00% | 0.00% | -1,568,550.00% | 0.00% |
| Income Tax Expense | 0.00 | 54.16M | 49.72M | 22.64M | 11.86M | 2.88M | 2.13M | 1.67M | 1.06M | 229.00K | 1.13M | 1.40M | 501.34K | 2.07M | 468.00K | 4.10M | -331.84K |
| Net Income | -209.25M | -287.82M | -318.82M | -166.19M | -109.02M | -201.81M | -166.99M | -74.98M | -49.78M | -36.38M | -26.09M | -11.74M | -10.82M | -28.73M | -24.93M | -27.58M | -10.67M |
| Net Income Ratio | -179.87% | -381.34% | -406.42% | -73.04% | -73.48% | -109.40% | 0.00% | 0.00% | 0.00% | 0.00% | -0.52% | 0.00% | 0.00% | 0.00% | 0.00% | -1,378,800.00% | 0.00% |
| EPS | -2.03 | -4.33 | -11.03 | -6.05 | -4.02 | -7.54 | -6.98 | -3.33 | -2.26 | -2.22 | -1.71 | -1.22 | -1.13 | -6.86 | -6.38 | -9.35 | -7.94 |
| EPS Diluted | -2.03 | -4.33 | -11.03 | -6.05 | -4.02 | -7.54 | -6.98 | -3.33 | -2.26 | -2.22 | -1.70 | -1.22 | -1.13 | -6.86 | -6.38 | -9.35 | -7.94 |
| Weighted Avg Shares Out | 103.11M | 66.41M | 28.90M | 27.47M | 27.09M | 26.75M | 23.93M | 22.54M | 22.02M | 16.37M | 15.29M | 9.61M | 9.61M | 4.19M | 3.91M | 2.95M | 1.34M |
| Weighted Avg Shares Out (Dil) | 103.11M | 66.41M | 28.90M | 27.47M | 27.09M | 26.75M | 23.93M | 22.54M | 22.02M | 16.37M | 15.34M | 9.61M | 9.61M | 4.19M | 3.91M | 2.95M | 1.34M |
Why Is Esperion Therapeutics (ESPR) Up 2% Since Last Earnings Report?
Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock?
Esperion to Participate in 23rd Annual Needham Virtual Healthcare Conference
ANN ARBOR, Mich., March 26, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced its participation in the 23rd Annual Needham Virtual Healthcare Conference. Sheldon Koenig, President and CEO, will participate in a fireside chat on Tuesday, April 9, 2024,...
Esperion Announces Data from CLEAR Outcomes Sub-Groups as Poster Presentations, Moderated Session & Industry Expert Theatre to be Presented at ACC.24
ANN ARBOR, Mich., March 25, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the acceptance of three CLEAR ( C holesterol L owering via B e mpedoic acid, an A CL-Inhibiting R egimen) Outcomes subgroup analyses as poster presentations...
U.S. FDA Approves Broad New Labels for Esperion's NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use
ANN ARBOR, Mich.--(BUSINESS WIRE)--Esperion (NASDAQ: ESPR) today announced that the United States Food and Drug Administration (FDA) has approved broad new label expansions for NEXLETOL® (bempedoic acid) Tablets and NEXLIZET® (bempedoic acid and ezetimibe) Tablets based on positive CLEAR Outcomes...
U.S. FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use
– New Labels Expand Treatable Population to ~70 Million Patients in U.S. – – First LDL-C Lowering Non-Statin Indicated for Primary Prevention Patients – – Approvals Based on Positive CLEAR Outcomes Data and Reflect a Highly Differentiated Product Profile –...
CHMP Issues Positive Opinions For Both Bempedoic Acid And The Bempedoic Acid / Ezetimibe Fixed-Dose Combination Tablet As Treatments For Hypercholesterolemia And Significantly Reducing Cardiovascular Events
– Positive CHMP Opinions Are Based On The Analyses Of The Phase 3 Of The CLEAR (Cholesterol Lowering via Bempedoic Acid, an ATP Citrate Lyase (ACL)-Inhibiting Regimen) Outcomes Trial 1 –
5 Small Drug Stocks to Buy From a Rebounding Industry
Innovation is expected to continue to drive growth of the Medical-Drugs industry. UTHR, ESPR, HRTX, LYRA and ALDX may prove to be good additions to one's portfolio.
A Relief Earnings Report Ahead Of An Inflection Point For Esperion Therapeutics
Esperion Therapeutics reported strong Q4 and full-year revenue growth, with total revenue increasing 72% YoY to $32.3M in Q4 and 54% YoY to $116M for the full year. The company expects a true inflection point after receiving approval for expanded...
Esperion (ESPR) Q4 Earnings Top, Stock Up on Strong Revenues
Esperion's (ESPR) fourth-quarter earnings and sales beat estimates on the back of better-than-expected collaboration revenues.
Esperion Therapeutics, Inc. (ESPR) Q4 2023 Earnings Call Transcript
Esperion Therapeutics, Inc. (ESPR) Q4 2023 Earnings Call Transcript
Source: https://incomestatements.info
Category: Stock Reports